Evidence map›Paper›PMID 37248318›Full record

ArticleScientific reports2023

Trends in diabetes incidence in Austria 2013-2017.

Michaela Kaleta, Michael Leutner, Stefan Thurner, Gottfried Endel, Noemi Kiss, Martin Robausch, Peter Klimek, Alexandra Kautzky-Willer

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Michaela KaletaSection for Science of Complex Systems, CeMSIIS, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Michael LeutnerUnit of Gender Medicine, Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Guertel 18-20, 1090, Vienna, Austria.
Stefan ThurnerSection for Science of Complex Systems, CeMSIIS, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Gottfried EndelAustrian Social Insurance (Dachverband der Sozialversicherungen), Kundmanngasse 21, 1030, Vienna, Austria.
Noemi KissAustrian Social Insurance (Dachverband der Sozialversicherungen), Kundmanngasse 21, 1030, Vienna, Austria.
Martin RobauschAustrian Health Insurance Fund (Österreichische Gesundheitskasse), Kremser Landstraße 3, 3100, St. Pölten, Austria.
Peter KlimekSection for Science of Complex Systems, CeMSIIS, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Alexandra Kautzky-WillerUnit of Gender Medicine, Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Guertel 18-20, 1090, Vienna, Austria. alexandra.kautzky-willer@meduniwien.ac.at.
Medical University of Vienna · ATWiener Krankenanstaltenverbund · ATComplexity Science Hub Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to quantify whether age and sex groups in Austrian regions are equally affected by the rise of type 2 diabetes. Population-wide medical claims data was obtained for citizens in Austria aged above 50 year, who received antihyperglycemic treatments or underwent HbA1c monitoring between 2012 and 2017. Diabetes incidence was measured using an epidemiological diabetes progression model accounting for patients who discontinued antihyperglycemic therapy; the erratic group. Out of 746,184 patients, 268,680 (140,960 females) discontinued their treatment and/or monitoring for at least one year. Without adjusting for such erratic patients, incidence rates increase from 2013 to 2017 (females: from 0·5% to 1·1%, males: 0·5% to 1·2%), whereas they decrease in all groups after adjustments (females: - 0·3% to - 0·5%, males: - 0·4% to - 0·5%). Higher mortality was observed in the erratic group compared to patients on continued antihyperglycemic therapy (mean difference 12% and 14% for females and males, respectively). In summary, incidence strongly depends on age, sex and place of residency. One out of three patients with diabetes in Austria discontinued antihyperglycemic treatment or glycemic monitoring for at least one year. This newly identified subgroup raises concern regarding adherence and continuous monitoring of diabetes care and demands further evaluation.

Indexed as

Diabetes Mellitus, Type 2AustriaDatasets as TopicFemaleHumansIncidenceInsurance, HealthMale

Identifiers

PMID37248318
PMCPMC10227037
OpenAlexW4378715369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.